Background Patients with psoriasis on biologic therapies and a history of viral hepatitis carry
a risk for reactivation. Objective We evaluated safety of biologic therapies in psoriasis …

Background The increasing use of biologics is accompanied by a risk of hepatitis B (HBV)
and C virus (HCV) reactivation. Objective To determine the predictors of HBV and HCV …

Considered more efficacious and safer than traditional systemic drugs, biologic therapies
have dramatically improved the quality of life of patients with psoriasis. Recently, there has …

Introduction and objectives A 5% risk of reactivation of hepatitis B virus (HBV) infection has
been reported in patients with diseases other than psoriasis treated with tumor necrosis …

Introduction There are no strong data regarding the treatment with biologics (especially for
the most recent anti-IL-17 and anti-IL-23 drugs) of patients with psoriasis and concomitant …

The use of anti‐tumor necrosis factor (TNF)‐α therapy in patients with psoriasis who are
hepatitis B virus (HBV) carriers is usually not recommended, and routine antiviral …

Background Ustekinumab, an interleukin (IL)‐12 and IL‐23 blocker, has emerged as a new
therapeutic option for patients with psoriasis. It is generally well tolerated but safety data on …

Abstract Background and Objectives Ustekinumab is used to treat moderate-to-severe
psoriasis by blocking the interleukin-12/23 pathway, which is also essential against …

The systemic therapies available for the management of Psoriasis (PsO) patients who
cannot be treated with more conservative options, such as topical agents and/or …

Background Little data are available about the safety of TNF‐α inhibitors in patients with
HCV and HBV infection. In particular, data concerning the use of adalimumab in patients …